Somewhat Favorable News Coverage Somewhat Unlikely to Impact Pacira Pharmaceuticals (PCRX) Stock Price
News articles about Pacira Pharmaceuticals (NASDAQ:PCRX) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pacira Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.4745977436842 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) – Trending Hot Stock’s Analysis – Nasdaq Journal (press release) (nasdaqjournal.com)
- $78.08 Million in Sales Expected for Pacira Pharmaceuticals, Inc. (PCRX) This Quarter (americanbankingnews.com)
- Theravance Biopharma (TBPH) and Pacira Pharmaceuticals (PCRX) Head to Head Survey (americanbankingnews.com)
- Pacira Pharmaceuticals, Inc. (PCRX) CEO David M. Stack Sells 28,885 Shares (americanbankingnews.com)
- Pacira Pharmaceuticals, Inc. (PCRX) Receives Average Rating of “Hold” from Brokerages (americanbankingnews.com)
PCRX has been the topic of several analyst reports. Bank of America dropped their price target on shares of Pacira Pharmaceuticals from $46.00 to $45.00 and set a “buy” rating on the stock in a research report on Wednesday, October 4th. Zacks Investment Research upgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price objective on the stock in a report on Tuesday, October 3rd. Canaccord Genuity reiterated a “buy” rating and issued a $44.00 price objective (down from $48.00) on shares of Pacira Pharmaceuticals in a report on Sunday, October 1st. Needham & Company LLC reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a report on Tuesday, September 26th. Finally, Mizuho reiterated a “buy” rating and issued a $53.00 price objective on shares of Pacira Pharmaceuticals in a report on Monday, September 25th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $49.00.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The business had revenue of $67.30 million for the quarter, compared to the consensus estimate of $68.99 million. During the same period in the prior year, the company posted $0.20 earnings per share. Pacira Pharmaceuticals’s revenue was down 1.6% compared to the same quarter last year. equities research analysts predict that Pacira Pharmaceuticals will post -0.85 EPS for the current year.
In related news, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $40.19, for a total value of $1,160,888.15. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mark A. Kronenfeld purchased 1,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was acquired at an average price of $41.60 per share, for a total transaction of $41,600.00. Following the completion of the purchase, the director now directly owns 6,795 shares of the company’s stock, valued at approximately $282,672. The disclosure for this purchase can be found here. Insiders sold 98,960 shares of company stock worth $3,868,341 over the last 90 days. 6.60% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-pacira-pharmaceuticals-pcrx-stock-price/1813559.html.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.